Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eksp Klin Gastroenterol ; (2): 41-9, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22808791

RESUMO

UNLABELLED: The objective of this study is to develop a marker panel of abnormalities of immune regulatory systems and cell genome in patients with gastric cancer for assessment of efficacy of surgical treatment in combination with pharmaco-nutritional therapy in early postoperative period. MATERIALS AND METHODS: Expression of p53, sFAS, FASL, CEA, and CA 19-9, nutritial status, as well as incidence of purulent-septic complications in early postoperative period were determined in 40 patients with gastric cancer (21 patients--the test group and 19 patients--the comparative group) prior to a curative surgical intervention, postoperative days 1 and 7, while the pharmaco-nutritional therapy (the test group) or partial parenteral nutrition (the comparative group) has been performed. RESULTS: The pharmaco-nutritional therapy significantly decreases in activity of tumor suppressing genome, lymphocyte apoptosis, expression of oncology-associated markers, incidence of purulent-septic complications, as well as exacerbation risk for hypotrophy in patients with gastric cancer in early postoperative period. CONCLUSION: To assess the efficacy of the surgical intervention performed in patients with gastric cancer, an expression of mutant p53 and markers of lymphocyte apoptosis (sFAS/FASL) is reasonable to be evaluated together with determination of oncomarkers (CEA and CA 19-9).


Assuntos
Biomarcadores Tumorais/sangue , Estado Nutricional , Apoio Nutricional/métodos , Neoplasias Gástricas/cirurgia , Idoso , Antígeno CA-19-9/sangue , Antígeno Carcinoembrionário/sangue , Proteína Ligante Fas/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Soluções de Nutrição Parenteral , Valor Preditivo dos Testes , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/terapia , Proteína Supressora de Tumor p53/sangue , Receptor fas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...